Image

Global Klinefelter Syndrome Treatment Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Klinefelter Syndrome Treatment Market, By Treatment (Testosterone Replacement Therapy, Fertility Treatment, Surgeries, Hormone Treatment, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, and Others) – Industry Trends and Forecast to 2030.

Klinefelter Syndrome Treatment Market

Klinefelter Syndrome Treatment Market Analysis and Size

According to the records of National Human Genome Research Institute, Klinefelter syndrome is found in around 1 out of every 500-1,000 newborn males. According to the researchers of national human research institutes, the syndrome cannot be diagnosed easily because of its unidentifiable symptoms and signs among males. There is no definitive treatment, though treatment is offered on the basis of symptoms in the patients. The treatment is provided for psychosocial problems and treatment of gynecomastia and hypogonadism, among others.

Data Bridge Market Research analyses a growth rate in the global klinefelter syndrome treatment market in the forecast period 2023-2030. The expected CAGR of global klinefelter syndrome treatment market tends to be around 4.46% in the mentioned forecast period. The market was valued at USD 1.08 billion in 2022, and it would grow to USD 1.54 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Klinefelter Syndrome Treatment Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Treatment (Testosterone Replacement Therapy, Fertility Treatment, Surgeries, Hormone Treatment, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, and Others)

Countries Covered

U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Hoffmann-La Roche Ltd. (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Kyowa Kirin Co., Ltd (Japan), Pfizer Inc (U.S., AstraZeneca (U.K.), Abbvie, Inc. (U.S.), Bausch Health Companies Inc. (U.S.)., Bristol Myers Squibb Company (U.S.) GSK Plc. (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), AstraZeneca (U.K.)

Market Opportunities

  • Increase in the number of research and development activities   
  • The emergence of new varied treatments

Market Definition

Klinefelter syndrome, also known as 47, XXY, is a genetic disorder where you have an extra X chromosome. This common chromosome disorder affects around one in five hundred people. Many people with Klinefelter syndrome never get diagnosed, though. The symptoms vary differently among patients, but few have no apparent signs of the disease. This syndrome may cause reduced muscle mass, body and facial hair, and enlarged breast tissue.

Global Klinefelter Syndrome Treatment Market Dynamics

Drivers

  • Increasing prevalence of Klinefelter syndrome

Klinefelter syndrome is considered the most common type of human sex chromosome disorder. It occurs in around 1 in every 500 to 1,000 males. Furthermore, every year, over 3,000 boys are born in the U.S. with this syndrome. This contributes to the growth of the market.

  • The growing change of changing lifestyles

The trending changing lifestyles of the people, leading to the increase in pregnancy rate after age 35, surges the risk of occurrence of Klinefelter syndrome. This would create demand for its treatment, helping drive the Klinefelter syndrome treatment market.

Opportunities

  • Increase in the number of product approvals       

The increased in focus of Klinefelter syndrome treatment market players on the development of newer products for the treatment of Klinefelter syndrome and major product approvals in the past few years have boosted the market's growth. For instance, in March 2019, Clarus Therapeutics received U.S. FDA approval for Jatenzo, an oral testosterone capsule that would help treat hypogonadism in Klinefelter syndrome patients. Furthermore, in April 2019, the U.S. FDA approved the marketing of a generic testosterone gel 1.62% developed by Lupin. This would help as a replacement therapy for men having hypogonadism.

  • The emergence of new varied treatments

The new evolving research organizations in the market are equipped with and utilize the knowledge of professionals in numerous clinical disciplines, leading to important advances in understanding Klinefelter-related disorders and treatment. For instance, Testosterone replacement therapy can also help with bone density, fracture prevention, and mood and behavior. It also corrects androgen deficiency, promoting body proportion normalization and the development of normal male secondary sex characteristics.

Restraints/Challenges

  • Limited treatment options

Not all males with XXY conditions can be benefitted from testosterone therapy. For instance, the benefits of taking testosterone for men whose testosterone levels are low to normal are less clear than for those whose testosterone levels are extremely low. Additionally, all possible side effects are acne, skin rashes from patches or gels, breathing issues, and an increased risk of an enlarged prostate gland or prostate cancer as you get older. Thus, this factor acts as a major hindrance to market growth.

  • High cost of treatment

The huge expenditure required for the treatment processes hampers the market growth. Numerous market players make huge investments in developing new and advanced treatment procedures to faster the recovery process, and in return, the cost is increased.

This global Klinefelter syndrome treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global Klinefelter syndrome treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Klinefelter Syndrome Treatment Market

COVID-19 infection was common in 10% of Klinefelter syndrome patients. The presence of an extra X chromosome in all infected patients leads to mild symptoms as the presence of an extra X chromosome influences a better clinical outcome. The development of infection was not protected by testicular atrophy. SARS-CoV-2 infection was majorly associated with the presence of one affected cohabitant. The link between SARS-CoV-2 and hypogonadism was confirmed, but the formulation of the TRT was unimportant. Therefore, COVID-19 is expected to impact market growth positively.

Global Klinefelter Syndrome Treatment Market Scope

The global klinefelter syndrome treatment market is segmented on the basis of treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

  • Testosterone Replacement Therapy
  • Fertility Treatment
  • Surgeries
  • Hormone Treatment
  • Others

End-Users

  • Hospitals
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies
  • Others

Klinefelter Syndrome Treatment Market Regional Analysis/Insights

The global klinefelter syndrome treatment market is analysed and market size insights and trends are provided by treatment, distribution channel and end-user as referenced above.

The major countries covered in the global klinefelter syndrome treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is dominating the market in the forecast period due to the growing production of testosterone in the region's developing countries.

Asia-Pacific is considered to grow over the coming years due to people's increased understanding of the Klinefelter syndrome condition.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Klinefelter Syndrome Treatment Market Share Analysis

The global klinefelter syndrome treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global klinefelter syndrome treatment market

Key players operating in the global klinefelter syndrome treatment market include:

  • Hoffmann-La Roche Ltd. (Switzerland)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Kyowa Kirin Co., Ltd (Japan)
  • Pfizer Inc (U.S.)
  • AstraZeneca (U.K.)
  • Abbvie, Inc. (U.S.)
  • Bausch Health Companies Inc. (U.S.).
  • Bristol Myers Squibb Company (U.S.)
  • GSK Plc. (U.S.
  •  Mylan N.V. (U.S.)
  • Novartis AG (Switzerland)
  • AstraZeneca (U.K.)  


SKU-
Why Choose Us


Frequently Asked Questions

The global Klinefelter syndrome treatment market was USD 1.08 billion in 2022.
The global Klinefelter syndrome treatment market is projected to grow at a CAGR of 4.46% during the forecast period of 2023-2030